The Goldman Sachs Group initiated coverage on shares of ConvaTec Group (LON:CTEC – Free Report) in a report issued on Tuesday, Marketbeat.com reports. The firm issued a buy rating and a GBX 300 ($3.79) price target on the stock.
Several other analysts have also recently issued reports on the stock. Barclays increased their target price on shares of ConvaTec Group from GBX 295 ($3.73) to GBX 300 ($3.79) and gave the stock an overweight rating in a research note on Friday, May 19th. JPMorgan Chase & Co. reiterated an overweight rating and issued a GBX 290 ($3.66) target price on shares of ConvaTec Group in a research note on Tuesday, June 27th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, ConvaTec Group currently has a consensus rating of Moderate Buy and an average price target of GBX 277 ($3.50).
ConvaTec Group Stock Performance
ConvaTec Group Cuts Dividend
The business also recently declared a dividend, which will be paid on Thursday, September 28th. Stockholders of record on Thursday, August 17th will be issued a $0.02 dividend. This represents a dividend yield of 0.67%. The ex-dividend date of this dividend is Thursday, August 17th. ConvaTec Group’s payout ratio is 16,666.67%.
ConvaTec Group Company Profile
ConvaTec Group PLC engages in the development, manufacture, and marketing of medical products and technologies worldwide. The company offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns.
- Five stocks we like better than ConvaTec Group
- What Investors Need to Know to Beat the Market
- 5 Ways to Play Retail that will Profit in 2023
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- This Is Why It’s Not Too Late For You To Buy Meta Stock
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- Why Analysts Say GE’s Healthcare Spinoff Has $20 Upside
Receive News & Ratings for ConvaTec Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConvaTec Group and related companies with MarketBeat.com's FREE daily email newsletter.